Tactile Systems (TCMD) Q4 2024 earnings summary

Executive summary

• Q4 revenue reached $85.6M, up 10.2% year-over-year, with full-year revenue at $293M, a 6.8%–7% annual increase.

• Gross margin improved by 310 basis points year-over-year in Q4, reaching 75.2%; full-year gross margin was 74%.

• Lymphedema product sales grew 11% year-over-year in Q4, with strong sequential growth and expanded Nimbl platform.

• Net income for Q4 was $9.7M ($0.40/diluted share), up 18.3% year-over-year; cash and cash equivalents ended at $94.4M.

• Served over 79,000 patients and promoted Aaron Snodgrass to SVP of Sales.

Financial highlights

• Q4 lymphedema product revenue: $77.1M (+11% year-over-year); airway clearance: $8.5M (+3.8%–4%).

• Q4 adjusted EBITDA was $16.2M (18.9% of sales), up 5% year-over-year; full-year adjusted EBITDA was $37.1M, up 25%.

• Q4 operating income was $12.5M (+6.1% year-over-year); Q4 operating margin was 14.6%.

• Operating cash flow for 2024 was $40.7M, up from $35.9M in 2023.

• Stock buyback of $3.5M completed in 2024; $26.5M remained in the repurchase program at year-end.

Outlook and guidance

• 2025 revenue guidance: $316–$322M, representing 8–10% year-over-year growth.

• Lymphedema product line expected to grow 8–10%; airway clearance 6–9% in 2025.

• GAAP gross margin for 2025 projected at ~74%; operating expenses to rise mid-double digits due to investments.

• Adjusted EBITDA for 2025 guided to $35–$37M.

• Revenue growth expected to accelerate in the second half of 2025 as strategic initiatives gain traction.